Canaccord kept its Buy rating and raised its target price from $10 per share to $13 per share, a positive analyst signal. The story reports no new company results, so the signal is limited.
This is a more favorable outside view of Aclaris, but it is still an analyst opinion, not proof that the company’s sales or treatments have improved. The story reports no new company results.
Follow Aclaris Therapeutics, Inc. (ACRS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ACRS